Clinical Trial Update: Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating ixazomib as a replacement for carfilzomib and bortezomib in multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• ixazomib (ixazomib)

Snippet

Sponsor: Oncotherapeutics | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED